Lecia V Sequist Selected Research

Adenocarcinoma

1/2019	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
1/2018	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
3/2016	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
9/2015	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
5/2012	Genetic changes in squamous cell lung cancer: a review.
7/2007	Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lecia V Sequist Research Topics

Disease

94	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 08/2005
88	Neoplasms (Cancer) 01/2022 - 07/2006
57	Lung Neoplasms (Lung Cancer) 10/2022 - 07/2006
20	Disease Progression 01/2022 - 08/2009
16	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2007
12	Adenocarcinoma of Lung 12/2018 - 07/2007
10	Circulating Neoplastic Cells 10/2018 - 07/2008
6	Adenocarcinoma 01/2019 - 07/2007
6	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 03/2010
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 10/2010
4	Dyspnea (Shortness of Breath) 06/2018 - 09/2013
4	Brain Neoplasms (Brain Tumor) 01/2018 - 11/2014
4	Melanoma (Melanoma, Malignant) 01/2018 - 07/2012
4	Fatigue 11/2016 - 09/2013
3	Central Nervous System Diseases (CNS Diseases) 06/2022 - 01/2018
3	Pneumonia (Pneumonitis) 01/2021 - 05/2008
3	Exanthema (Rash) 01/2020 - 09/2013
3	Epilepsy (Aura) 01/2019 - 04/2017
3	Cough 01/2018 - 09/2013
3	Pain (Aches) 01/2018 - 09/2013
3	Diarrhea 09/2013 - 06/2010
2	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 02/2015
2	Acute Kidney Injury (Acute Renal Failure) 01/2020 - 11/2016
2	Neutropenia 11/2016 - 02/2015
2	Stomatitis 02/2015 - 09/2013
2	Acne Vulgaris 02/2015 - 09/2013
2	Nausea 09/2013 - 09/2013
1	COVID-19 01/2021
1	medullary Thyroid cancer 01/2020
1	Pneumothorax 12/2019

Drug/Important Bio-Agent (IBA)

73	ErbB Receptors (EGF Receptor)IBA 01/2021 - 08/2005
48	Tyrosine Kinase InhibitorsIBA 10/2022 - 01/2007
22	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 07/2006
14	RNA (Ribonucleic Acid)IBA 12/2018 - 03/2010
13	AfatinibIBA 01/2021 - 05/2012
12	osimertinibIBA 06/2022 - 04/2016
11	Pharmaceutical PreparationsIBA 11/2020 - 06/2008
11	Gefitinib (Iressa)FDA Link 01/2019 - 07/2006
10	Phosphotransferases (Kinase)IBA 01/2022 - 08/2005
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2007
9	PlatinumIBA 01/2022 - 02/2010
8	CrizotinibIBA 01/2021 - 06/2010
8	Biological ProductsIBA 11/2020 - 03/2007
8	Anaplastic Lymphoma KinaseIBA 01/2020 - 06/2010
8	Pemetrexed (MTA)FDA Link 11/2016 - 10/2008
7	rociletinibIBA 11/2018 - 01/2015
7	Cisplatin (Platino)FDA LinkGeneric 03/2016 - 11/2008
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2007
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 05/2008
5	Immune Checkpoint InhibitorsIBA 01/2021 - 06/2015
4	Circulating Tumor DNAIBA 01/2020 - 03/2016
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2018 - 07/2012
4	ARQ 197IBA 01/2018 - 08/2011
3	lorlatinibIBA 10/2022 - 01/2021
3	Bevacizumab (Avastin)FDA Link 01/2022 - 10/2008
3	nazartinibIBA 01/2022 - 01/2018
3	pembrolizumabIBA 01/2019 - 11/2016
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 03/2013
3	Docetaxel (Taxotere)FDA Link 01/2019 - 01/2015
3	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2019 - 12/2012
3	Androgen Receptors (Androgen Receptor)IBA 11/2017 - 11/2012
3	Carboplatin (JM8)FDA LinkGeneric 11/2016 - 11/2009
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2010 - 07/2006
2	cabozantinibIBA 01/2022 - 01/2021
2	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2017
2	olaparibIBA 10/2019 - 10/2013
2	Messenger RNA (mRNA)IBA 01/2019 - 12/2018
2	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 12/2018 - 01/2018
2	NivolumabIBA 10/2018 - 06/2015
2	Complement System Proteins (Complement)IBA 12/2017 - 01/2016
2	Interleukin-6 (Interleukin 6)IBA 11/2017 - 01/2017
2	EpitopesIBA 10/2017 - 04/2013
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2017 - 12/2014
2	alectinibIBA 11/2016 - 10/2016
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 10/2015 - 10/2012
2	AndrogensIBA 09/2015 - 11/2012
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 06/2013 - 11/2010
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	entrectinibIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	capmatinibIBA 01/2021
1	selpercatinibIBA 01/2020
1	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2020
1	SolventsIBA 01/2020
1	Temozolomide (Temodar)FDA LinkGeneric 10/2019
1	IpilimumabIBA 01/2019
1	seribantumabIBA 01/2019
1	histidine-rich proteinsIBA 01/2019

Therapy/Procedure

71	Therapeutics 01/2022 - 07/2006
28	Drug Therapy (Chemotherapy) 01/2022 - 02/2007
9	Radiotherapy 01/2022 - 02/2015
3	Immunotherapy 01/2022 - 01/2015
3	Castration 01/2018 - 11/2012
3	Aftercare (After-Treatment) 01/2018 - 06/2007
3	Lab-On-A-Chip Devices 11/2014 - 07/2008
2	Drug Tapering 01/2020 - 06/2010
1	Surgical Instruments (Clip) 01/2020
1	Chest Tubes (Chest Tube) 12/2019
1	Adjuvant Chemotherapy 10/2019
1	Time-to-Treatment 01/2019